- Home
- RMAX vs TLSI Comparison
RMAX vs TLSI Comparison
Compare RMAX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- TLSI
- Stock Information
- Founded
- RMAX 1973
- TLSI 2010
- Country
- RMAX United States
- TLSI United States
- Employees
- RMAX N/A
- TLSI N/A
- Industry
- RMAX Real Estate
- TLSI Medical Specialities
- Sector
- RMAX Finance
- TLSI Health Care
- Exchange
- RMAX Nasdaq
- TLSI Nasdaq
- Market Cap
- RMAX 178.3M
- TLSI 150.0M
- IPO Year
- RMAX 2013
- TLSI N/A
- Fundamental
- Price
- RMAX $9.44
- TLSI $5.22
- Analyst Decision
- RMAX Hold
- TLSI Strong Buy
- Analyst Count
- RMAX 1
- TLSI 5
- Target Price
- RMAX $9.00
- TLSI $10.90
- AVG Volume (30 Days)
- RMAX 267.6K
- TLSI 120.0K
- Earning Date
- RMAX 07-29-2025
- TLSI 08-12-2025
- Dividend Yield
- RMAX N/A
- TLSI N/A
- EPS Growth
- RMAX N/A
- TLSI N/A
- EPS
- RMAX 0.48
- TLSI N/A
- Revenue
- RMAX $298,162,000.00
- TLSI $35,990,000.00
- Revenue This Year
- RMAX N/A
- TLSI $56.79
- Revenue Next Year
- RMAX $1.45
- TLSI $54.15
- P/E Ratio
- RMAX $19.44
- TLSI N/A
- Revenue Growth
- RMAX N/A
- TLSI 45.50
- 52 Week Low
- RMAX $6.90
- TLSI $3.42
- 52 Week High
- RMAX $14.31
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- RMAX 64.53
- TLSI 61.96
- Support Level
- RMAX $9.22
- TLSI $4.78
- Resistance Level
- RMAX $9.52
- TLSI $5.33
- Average True Range (ATR)
- RMAX 0.36
- TLSI 0.43
- MACD
- RMAX 0.08
- TLSI 0.11
- Stochastic Oscillator
- RMAX 85.76
- TLSI 94.09
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.